NCT07876531Not yet recruitingPhase 1
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
PHASE 1, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, PK COMPARABILITY STUDY BETWEEN DIFFERENT DELIVERY SYSTEMS OF BEROBENATIDE IN ADULTS WITH OVERWEIGHT OR OBESITY
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy. The study involves multiple clinic visits at a study site over the length of the study.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 9 Oct 2026
- Start date
- Oct 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Pfizer
- Diseases
- Obesity
- NCT number
- NCT07876531
- EU CT number
- 2025-524803-65-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 144
- From Oct 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect gastrointestinal (GI) motility
- Acute GI symptoms at screening, Day -1, or prior to administration of study intervention
Other illness
- History of other chronic disorders
- Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC
Other
- Pregnant or breastfeeding women, or those planning pregnancy during the study
Who the study is looking for
- Participants 18 years of age or older
- BMI of 27-45 kg/m2; and a total body weight \>50 kg (110 lb)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anaheim Clinical Trials, LLC Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.